secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2026-09-22T11:08:26+00:00
Accession:  0000886163-26-000050
Event type: m_and_a
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand buys Santen's Ryjunea royalty rights for $23M upfront
------------------------------------------------------------

- $23M upfront acquires 100% interest in tiered low-double-digit-to-high-teens royalty on Ryjunea EMEA net sales.
- Ryjunea is EU/UK's first approved pharmacologic treatment to slow pediatric myopia; EC approved June 2025, UK MHRA Oct 2025.
- Santen licensed EMEA rights from Sydnexis in 2021; Ligand steps into those payment rights; Sydnexis keeps US and other territories.
- Market: ~14M myopia patients in Europe 2025; 1 in 3 children projected affected by 2050.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616326000050/0000886163-26-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616326000050/lgnd-20260922.htm
  HTML page:      https://secwatch.observer/filing/0000886163-26-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer